Vogenx (VOGX)
Develops an oral SGLT1 inhibitor for post-bariatric hypoglycemia.
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
LOS ANGELES and NEW YORK, Aug. 17, 2026 /PRNewswire/ -- JonesTrading Institutional Services LLC ("Jones") today announced that it served as sole book-running manager for the $81.3 million initial public offering of Vogenx, Inc. (NASDAQ: VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism. The offering consisted of 6,250,000 shares of Vogenx common stock at a public offering price of $13.00 per share, at the high end of the proposed range.
Vogenx Announces Closing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 13, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the closing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $13.00 per share. All of the shares were offered by Vogenx.
Vogenx Announces Pricing of Initial Public Offering
RALEIGH, NC / ACCESS Newswire / August 11, 2026 / Vogenx, Inc. (NASDAQ:VOGX) ("Vogenx"), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at the high end of the range at a public offering price of $13.00 per share. All of the shares are being offered by Vogenx.
